We are live on ! Find out more
PYXS icon

Pyxis Oncology

101 hedge funds and large institutions have $190M invested in Pyxis Oncology in 2026 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 26 increasing their positions, 19 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,866% more capital inflows, than outflows

Capital inflows: $146M | Capital outflows: $7.42M

379% more call options, than puts

Call options by funds: $1.21M | Put options by funds: $253K

200% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 13

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

72.02% more ownership

Funds ownership: 53.91% → 125.92% (+72%)

37% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 19

33% more funds holding

Funds holding: 76 → 101 (+25)

Holders
101
Holders Change
+25
Holders Change %
+32.89%
% of All Funds
1.24%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
39
Increased
26
Reduced
19
Closed
13
Calls
$1.21M
Puts
$253K
Net Calls
+$958K
Net Calls Change
-$622K

PYXS Hedge Fund Activity: Q3 2026 in Review

101 of the 8,154 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q3 2026, worth a combined $190M — up 88% from $101M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new PYXS positions and 13 closed out — a net gain of 26 holders — while 26 added to existing stakes and 19 trimmed.

The largest buyer was BVF Inc, opening a new position worth an estimated $35.8M. The largest seller was Woodline Partners, exiting entirely with an estimated $1.58M sold.

  • 101 institutional investors held Pyxis Oncology (PYXS) as of Q3 2026, up from 76 in Q2 2026.
  • Funds reported $190M of Pyxis Oncology stock for Q3 2026, up 88% quarter-over-quarter.
  • 39 funds opened new Pyxis Oncology positions in Q3 2026 and 13 closed out, a net change of +26 holders.
  • The largest Pyxis Oncology buyer in Q3 2026 was BVF Inc, an estimated $35.8M added.
  • The largest Pyxis Oncology seller in Q3 2026 was Woodline Partners, an estimated $1.58M sold.

Based on aggregated 13F filings for Q3 2026.